Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis technology platform, presented an analysis of data from its Phase 2 clinical trial showing that treatment with AGS-003, the company's lead ... (more)
http://www.biospace.com/news_story.aspx?StoryID=315231&full=1
http://www.biospace.com/news_story.aspx?StoryID=315231&full=1
No comments:
Post a Comment